Repeat Oral Dose SCY-247 Exceeds Exposures Associated with Efficacy in Murine Models of Invasive Candidiasis with Low Potential for Drug-Drug Interactions with Key CYP450s

In vitro Efficacy of Second-Generation Triterpenoid Antifungal, SCY-247, against Multidrug- and Pandrug-resistant Candida auris

In vitro activity of SCY-247 and comparators against clinical isolates of Aspergillus spp. and Lomentospora prolificans

Three Months of SCY-247 EUCAST MIC Testing: Uniform Activity against Candida Species and no Cross-Resistance to Echinocandins

Efficacy of once or twice daily oral SCY-247, a second-generation triterpenoid antifungal, in a murine model of Candida auris infection

SCY-247 demonstrates high in vitro activity against genetically diverse C. auris isolates, including FKS1 mutants

The Novel Second-Generation IV/Oral Triterpenoid SCY-247 Maintains In vitro and In vivo Activity against Resistant Candida glabrata

Antifungal susceptibility testing of SCY-247 against contemporary clinical yeast isolates

SCY-247, a novel antifungal, demonstrates in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants

The new triterpenoid antifungal SCY-247 retained activity against most echinocandin and fluconazole-resistant Candida spp isolates: reduced susceptibility against C. glabrata isolates showing substitutions at the first amino acid in hotspot 1 FKS2 gene